Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,215 across all filing types
Latest filing 2021-04-19 Annual Report
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
2020 Annual Report
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2020' and contains detailed sections typical of an annual report, including Chairman's Statement, Management Discussion and Analysis, Corporate Governance Report, Environmental, Social and Governance Report, Report of the Directors, Independent Auditor's Report, and full consolidated financial statements with notes. The content covers comprehensive financial performance, business review, product sales, research and development, and dividend distribution for the fiscal year ended 31 December 2020. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-04-19 English
CONTINUING CONNECTED TRANSACTIONS - MASTER SALE AND PURCHASE AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement related to a Master Sale and Purchase Agreement involving continuing connected transactions between the company and a substantial shareholder (Sichuan Kelun). It discusses the terms, pricing policies, annual caps, and regulatory requirements under the Hong Kong Listing Rules Chapter 14A. The document includes details about the agreement, conditions precedent, and the need for shareholder approval at an Extraordinary General Meeting (EGM). It is a regulatory announcement about a continuing connected transaction and related corporate governance matters, not a financial report, earnings release, or management discussion. It is not a proxy statement or voting results announcement but rather a detailed announcement of a continuing connected transaction requiring shareholder approval. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about connected transactions and compliance with listing rules, without being a full financial report or other specific filing type.
2021-04-14 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors regarding the approval of a drug product by a regulatory authority in China. It is an update on product development and does not contain financial statements, detailed financial data, or regulatory certifications. The document is relatively short (1691 characters) and serves to inform shareholders and investors about business progress rather than reporting financial results or governance changes. It is not an annual or interim report, earnings release, or management discussion. It is also not a regulatory filing or certification. The content fits best as a general regulatory announcement or business update, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2021-04-12 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/03/2021, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and confirmations related to securities issuance, typical of regulatory filings required by stock exchanges to report share capital movements. There is no indication of financial performance data, management discussion, earnings, or audit information. The document is a regulatory compliance report on share capital movements rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS). The document length is substantial (15,000 characters), indicating it is not a brief announcement but a detailed regulatory filing.
2021-04-01 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020
Annual Report Classification · 95% confidence The document is an announcement titled 'ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020' and contains detailed financial results, business review, sales data, and research and development updates for the full fiscal year 2020. It includes comprehensive financial performance metrics such as revenue, profit, dividend distribution, and product sales breakdown. The length of the document is substantial (15,000 characters), and it contains actual financial data and analysis rather than just a brief announcement or a link to a report. The content matches the characteristics of an Annual Report or a full-year financial report. Therefore, the document should be classified as an Annual Report (10-K). FY 2020
2021-03-30 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding the approval of a new drug product by a regulatory authority. It is an update on product development and does not contain financial data, financial results, or detailed report content. The document is short (1636 characters) and serves to inform shareholders and investors about business developments rather than presenting a formal report or financial statements. It is not an annual report, interim report, earnings release, or any other formal financial filing. It is also not a regulatory filing in the sense of compliance or certification, nor is it a management or governance report. The content fits best as a general regulatory announcement or business update. Given the options, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2021-03-25 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.